Loading viewer...
investor_presentation
Format: PDF investor_presentation
Veeco Instruments Inc. November 1, 2018Q3 2018 Conference Call
Veeco Instruments Inc.
November 1, 2018Q3 2018
Conference CallSafe Harbor
To the extent that this presentation discusses expectations or otherwise makes
statements about the future, such statements are forward -looking and are subject to
a number of risks and uncertainties that could cause actual results to differ materially
from the statements made.
These items include the risk factors discussed in the Business Description and
Management's Discussion and Analysis sections of Veeco's Annual Report on
Form 10 -K for the year ended December 31, 2017 and subsequent Quarterly Reports
on Form 10 -Q and current reports on Form 8 -K. Veeco does not undertake any obligation
to update any forward -looking statements to reflect future events or circumstances
after the date of such statements.
Q3 2018 Conference Call | © 2018 Veeco Instruments Inc. 2CEO Introduction
William J. Miller, Ph.D.Q3 2018 Highlights
•Bookings growth in Front -End Semiconductor
•Ending backlog of $276M•Profitability above the mid -point of guidance
•Generated positive cash flow
•Repurchased 1.8% of outstanding shares
4Transitioning MOCVD from Commodity LED to Compound Semiconductor MarketQ3
A reconciliation of GAAP to Non -GAAP financial measures can be found in the backup section of this presentation.
Q3 2018 Conference Call | © 2018 Veeco Instruments Inc.CFO Financial Review
Sam MaheshwariExpense Reduction Update
6Carefully Executing OpEx Reduction –Reducing SG&A while Preserving R&D OpEx Reductions
Q3 2018 Conference Call | © 2018 Veeco Instruments Inc.Amounts may not calculate precisely due to roundingQ3 2017 Target Q2 2019SG&A
$40MInitiative Status
($15M annually)•Complete by Q1 2019
New initiative to align cost
structure with business conditions
($20M annually)•In process
Preview truncated — download the full document for the complete content.
investor_presentation
30 Pages
investor_presentation
32 Pages
Regeneron Pharmaceuticals, Inc.
investor_presentation
Macy's